Compare WKEY & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WKEY | MNOV |
|---|---|---|
| Founded | 1999 | 2000 |
| Country | Switzerland | United States |
| Employees | 102 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.5M | 66.9M |
| IPO Year | N/A | 2004 |
| Metric | WKEY | MNOV |
|---|---|---|
| Price | $7.25 | $1.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $10.50 | $7.50 |
| AVG Volume (30 Days) | ★ 90.1K | 48.6K |
| Earning Date | 01-28-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,360,807.00 |
| Revenue This Year | $31.22 | N/A |
| Revenue Next Year | $91.39 | $180.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 194.15 |
| 52 Week Low | $3.26 | $1.17 |
| 52 Week High | $19.80 | $1.96 |
| Indicator | WKEY | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 58.58 | 49.25 |
| Support Level | $6.43 | $1.40 |
| Resistance Level | $7.56 | $1.60 |
| Average True Range (ATR) | 0.47 | 0.06 |
| MACD | 0.12 | 0.01 |
| Stochastic Oscillator | 90.43 | 41.18 |
WISeKey International Holding Ltd is a cybersecurity company focused on delivering integrated security solutions for the Internet of Things and digital identity ecosystems. It integrates secure semiconductors, cybersecurity software, and a globally recognized Root of Trust (RoT) into products and services that protect users, devices, data and transactions in the internet-connected world. It has two business segments. The IoT segment, which is the key revenue driver, generates revenue from the sale of semiconductor's secure chips. The mPKI segment generates revenues from Digital Certificates, It derives maximum revenue from IoT segment.
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.